Purification and molecular characterization of phospholipase, antigen 5 and hyaluronidases from the venom of the Asian hornet (Vespa velutina).

The aim of this study was to purify potential allergenic components of Vespa velutina venom, the yellow legged Asian Hornet, and perform a preliminary characterization of the purified proteins. Starting from the whole venom of V.velutina, several chromatographic steps allowed to purify the phospholipase (named Vesp v 1), as well as the antigen 5 (Vesp v 5, the only allergenic component described as such so far). The two hyaluronidase isoforms found (Vesp v 2A and Vesp v 2B) cannot be separated from each other, but they are partially purified and characterized. Purity of the isolated proteins in shown by SDSPAGE, as well as by the results of the N-terminal sequencing. This characterization and nLC-MS/MS data provide most of the sequence for Vesp v 1 and Vesp v 5 (72 and 84% coverage, respectively), confirming that the whole sequences of the isolated natural components match with the data available in public transcriptomic databases. It is of particular interest that Vesp v 1 is a glycosylated phospholipase, a fact that had only described so far for the corresponding allergen components of Dolichovespula maculata and Solenopsis invicta. The availability of the complete sequences of Vespa velutina components permits comparison with homologous sequences from other Hymenoptera. These data demonstrate the higher similarity among the species of the genera Vespa and Vespula, in comparison to Polistes species, as it is especially observed with the hyaluronidases isoforms: the isoform Vesp v 2A only exists in the former genera, and not in Polistes; in addition, the most abundant isoform (Vesp v 2B) exhibits 93% sequence identity with the Ves v 2 isoform of Vespula vulgaris. Finally, the isolated components might be useful for improving the diagnosis of patients that could be allergic to stings of this invasive Asian hornet, as it has been the case of an improved diagnosis and treatment of other Hymenoptera-sensitized patients.

Introduction

The “yellow-legged”-Asian hornet (Vespa velutina nigrithorax) is an invasive species that was originally introduced in the Iberian Peninsula through France, having been identified in Spain for the first time in 2010 [1]. Since then, it has extended its presence through the north of Spain, up to the north of Portugal, causing socio-economic concerns due to its important expansive capacity, also considering that they frequently attack honey-bee hives to feed their nests. Solutions for this invasion are being considered in different ways in several European countries [2-5]. From the allergologic point of view, it is also a concern, as demonstrated in the North of Spain [6], when the first cases of anaphylactic shocks were described, and when “antigen 5”, from the venom of these Asian hornets, was identified as the most important allergen in a group of eight sensitized patients.

The data we have obtained from these purified components, confirm the whole sequence data available in transcriptomic databases since 2015 [7], and this allows a thorough comparison with homologous components from other Hymenoptera. Moreover, the purified components will be used to demonstrate their relevance as allergens, by Component Resolved Diagnosis (CRD), in studies performed in platforms that can measure specific IgE in the sera of allergic patients ([8,9]), which are useful to differentiate which can be the sensitizing species for each patient, as we also published in the past ([10]), differentiating on Vespula versus. Polistes sensititization.

The nomenclature used for naming the purified components, will consider what is suggested for allergenic proteins by the WHO/IUIS (World Health Organization / International Union of Immunological Societies) Committee ([11,12]), considering that only the antigen 5 (named Vesp v 5) has been described as such so far; the phospholipase (Vesp v 1) and hyaluronidases (Vesp v 2) must still be considered as potential allergenic components.

In summary, in this work we isolate the main potential allergenic components of the V.velutina venom, and show the potential interest on the availability of these purified components: their characterization allow a closer understanding of similarities among different Hymenoptera venom components, and will surely be useful in a better diagnosis and treatment of allergic patients to stings of this Asian hornet.

Materials and methods

The relevant natural venom components (A1 phospholipase, antigen 5 and hyaluronidases) were purified from lyophilized Vespa velutina venom sac extract of individual hornets collected in Europe (ALK Source Materials Inc., Spring Mills, U.S.A.; batch 01071301AH). The purification was performed as previously described [13,14], and in a similar manner as performed with other natural allergens from Vespula vulgaris and Polistes dominula [10]. The purified proteins were analysed by SDS–PAGE (Novex-Tricine, 10–20% acrylamide, Invitrogen Life Technologies, Carlsbad, CA, U.S.A.) and silver- or Coomassie blue-stained, depending on the needs of the analysis (SDSPAGE was silver stained, according to [15]). The enzymatic activity of phospholipase and hyaluronidases was verified when needed by the methods of Habermann [16] and Richman and Baer [17], respectively, using Apis mellifera venom (ALK Source Materials Inc., Spring Mills, U.S.A.) preparation as reference.

The purity and identity of the purified proteins was also confirmed, according to [18], by N-terminal sequencing analyses (direct analysis of the protein in solution), performed at CIB Protein Chemistry Service (CSIC, Madrid, Spain).

In the case of Vesp v 1 and Vesp v 5 additional nLC-MS/MS (nano Liquid Chromatography tandem mass spectrometry) analyses were performed from the bands extracted from an SDSPAGE stained with Coomassie blue (Colloidal Blue Staining, LC6025, Invitrogen Life Technologies, Carlsbad, CA, U.S.A.): this protein identification by nLC-MS/MS was carried out in the Proteomics and Genomics Facility (CIB-CSIC, Madrid—Spain), a member of ProteoRed-ISCIII network, according to the method described in [19]. For the MS analysis, Peptides were trapped onto a Acclaim PepMap 100 (Thermo Fisher Scientific Inc., Waltham, MA U.S.A.) precolumn, and then eluted onto a column Acclaim PepMap 100 C18 column, inner diameter 75 μm, 25 cm long, 3 μm particle size (Thermo Fisher Scientific Inc., Waltham, MA U.S.A.) and separated using a 130 min gradient (100 min from 0% -35% Buffer B; 20 min from 35% -45% Buffer B; 5 min from 45% -95% Buffer B; 4min 95% Buffer B and 1 min 0% Buffer B; (Buffer A: 0.1% formic acid, 2% acetonitrile and Buffer B: 0.1% formic acid in acetonitrile) at a flow-rate of 250 nL/min on a nanoEasy HPLC (Proxeon) coupled to a nanoelectrospray (Thermo Fisher Scientific). Mass spectra were acquired on a LTQ-Orbitrap Velos mass spectrometer (Thermo Fisher Scientific) in the positive ion mode. Full-scan MS spectra (m/z 300–18000) were acquired in the Orbitrap at a resolution of 60,000 and the 15 most intense ions were selected for collision induced dissociation (CID) fragmentation in the linear ion trap with a normalized collision energy of 35%. Singly charged ions and unassigned charge states were rejected. Dynamic exclusion was enabled with exclusion duration of 45 s.

MS data were analysed according to [19], Mass spectra raw files were searched against an in–house specific database with known venom allergen sequences and sequences extracted from transcriptomic databases, using the Sequest search engine through Proteome Discoverer (version 1.4.1.14) (Thermo Fisher Scientific). Search parameters included a maximum of two missed cleavages allowed, carbamidomethyl of cysteines as a fixed modification and oxidation of methionine as variable modifications. Precursor and fragment mass tolerance were set to 10 ppm and 0.5 Da, respectively. Identified peptides were validated using Percolator algorithm with a q-value threshold of 0.01. The data generated by these procedures, that has allowed the characterization of the Vespa velutina components included in this manuscript are available at the Mass spectrometry Interactive Virtual Enviroment (MassIVE), with the reference PXD015381 as ProteomeExchange identifier.

The publicly available transcriptomic data for the Asian hornet Vespa velutina nigrithorax [7] was downloaded from the GEO database (SRA experiment SRX595647). The sequence data was originally obtained from RNA extracted from the venom glands of Asian hornet species collected in China ([7]). Using the FASTX-Toolkit (http://hannonlab.cshl.edu/fastx_toolkit/), the sequencing reads were trimmed and filtered with respect to quality, trimming bases from the ends with quality score below 20 and keeping reads that were at least 50 bases long after trimming, resulting in 203,886,099 reads (99.9% of the original data set). De novo transcriptome assembly was performed using the Trinity software (v2.1.1) [20]. From the assembled transcript sequences, the “coding sequence” or CDS (sequences corresponding to the natural proteins in the Open Reading Frames) can be extracted for further analyses.

Nomenclature used for the potential allergenic molecules of Vespa velutina venom, follow the rules recommended by the WHO/IUIS Committee ([11,12]). Protein parameters from the protein sequences (e.g. molecular weight calculation, extinction coefficients, prediction of N-glycosylation, etc.) and alignments were obtained from the software package at the Expasy Bioinformatic portal at the SIB (Swiss Institute of Bioinformatics) [21]. Furthermore, sequence homology searches were performed with the program BLAST (Basic Local Alignment Tool) [22]) provided by the NCBI (National Centre of Biotechnology Information, U.S. National Library of Medicine, Bethesda, USA).

Results and discussion

Vesp v 1, the A1-phospholipase from the venom sac extract was purified as in [13], by directly using as specific affinity chromatography (Fig 1) followed by an ion exchange chromatography (Mono-S column, GE Healthcare, Upsala, Sweden). The flowthrough (FT) from the previous affinity chromatography was applied onto a Heparin-Sepharose column (GE-Heathcare, Upsala, Sweden) (Fig 2), which permits the separation of Vesp v 5 and of two isoforms of Hyaluronidase (namely, Vesp v 2A and 2B). Final purification of Vesp v 5 is achieved by an additional Size-Exclusion-Chromatography (SEC) on a Superdex75 column (GE Helthcare, Upsala, Sweden). In the chromatographic profile shown in Fig 2, and additional test was performed in some fractions: the measurement of the relative specific activity of hyaluronidases by the method of Richman ([17]). These measurements just show the presence of hyaluronidase in such fractions, and this can only be considered as a semi-quantitative approach. The data in Fig 2 show the wheal size in the agarose plate and the fractions in which there is a higher (***) or lower (*) hyaluronidase activity (compared with the positive control used in these assays, as indicated in [17]). Moreover, the data shown in the SDSPAGE inserted in Fig 2, clearly shows the presence of the two hyaluronidase isoforms (mainly in fractions c, d and e), as well of the importance of the final SEC step for purifying Vesp v 5.

Fig 1

Elution profile of PC-Sepharose and SDSPAGE analysis.

This affinity chromatography corresponds to the initial separation of the components of the Vespa velutina extract. Absorbance at 280nm (black line) and 215nm (red line) show the eluting components (“mAU” corresponds to milli-absorbance units). The second right axis corresponds to pH during the elution (green line), and it can be observed that the phospholipase elution occurs when the pH decreases (the Vesp v 1 peak, as indicated by an arrow). The rest of the venom components elute in the “Flowthrough” (F.T., shown with a horizontal double-arrow). The SDSPAGE in the inset shows the proteins separated in these steps: Lane 1 corresponds to the initial extract, lane 2 corresponds to the FT, and lane 3 to the Vesp v 1 peak. Lane P shows the purified Vesp v 1 (0.25μg), after the final ion-exchange chromatography on a mono-S column. Lane M corresponds to the molecular weight markers (BioRad Precision Blue, BIORAD, Hercules, CA U.S.A.), and their size in kDa are shown on the left margin of the SDSPAGE inset. SDSPAGE shown are silver stained ([15]).

Fig 2

Elution profile of Heparin-Sepharose column and SDSPAGE analysis.

This chromatographic profile shows the separation of the components coming from the FT of the chromatography in Fig 1 (absorbance at 280nm represented as ________) due to the effect of the NaCl gradient (conductivity, in mS/cm, represented as …………): Vesp v 5 elutes as the major peak, clearly separated from the Vesp v 2 hyaluronidases isoforms. In the inserted silver-stained SDSPAGE, the left panel shows consecutive fractions of the chromatography (fractions a, b, c, d, e, whose positions are shown by blue arrows); in addition to the electrophoretic result, the inserted table shows the relative hyaluronidase activity measured in those fractions (expressed in cm, as the size of the wheal in the agarose plate, or indicating its higher “***” or lower “*” relative activity). Finally, the right panel shows the purified Vesp v 5 (lane V, 0.25μg), a blank lane (--) and molecular weight markers (lane M). The molecular weight in kDa for the BioRad Precision Blue are shown on the right margin of the SDSPAGE inset.

The proteins purified have been analyzed by direct N-terminal protein sequencing (Edman degradation), showing the results presented in Table 1. In the case of Vesp v 2, it is clear that there are two proteins (confirming what it was mentioned in the SDSPAGE of Fig 2), and their sequences correspond to the first 10 residues of each of the isoforms found in the Vespa velutina transcriptome databases (Fig 3); moreover, the experimental data show that one of the isoforms is clearly the most abundant (isoform B), and this is coincident with what has also been described for the corresponding isoform of Ves v 2 (allergen component from Vespula vulgaris) [23]. The data obtained in the N-terminal sequencing also demonstrates that the Asn in 3rd position of isoform A must be glycosylated (wasps and hornet hyaluronidases are known to be glycosylated; e.g. Ves v 2 in known to contain at least 3 glycosylation sites [24]). This is also confirmed by the apparent molecular weight exhibited by the two isoforms (40.0–41.7kDa, as calculated from the SDS-PAGE, Fig 2), which are higher than the 39.1 and 40.0kDa values that correspond to the polypeptide part of the complete “coding sequence” or CDS (Fig 3) of isoforms A and B, respectively (Protein Parameters determined in [21]). Fig 3 also shows the positions of the predicted glycosylation sites for each isoform of Vesp v 2 (four potential sites in each of them).

Table 1

N-terminal sequences determined for the purified proteins of the venom of V.velutina.

The sequential result of the amino acids resulting from the Edman degradation are shown (in the case of Vesp v 1 and Vesp v 5 only 5 sequencing cycles were performed). In the column at right, the corresponding accession numbers assigned to each protein in the UniProt Knowledgebase are shown. The purified proteins are named considering their potential allergenic nomenclature, even if the only major allergen confirmed to date is Vesp v 5, as approved by the WHO/IUIS Committee ([11,12]), and included in their allergen database at “www.allergen.org”.

Protein	N-terminal sequencing results										UNIPROT #
Vesp v 2A	Asn	Leu	(*)Asn	Arg	Thr	Asn	Trp	Pro	Lys	Lys…	C0HLL4
Vesp v 2B	Ser	Glu	Arg	Pro	Lys	Arg	Val	Phe	Asn	Ile…	C0HLL5
Vesp v 1	Gly	Leu	Leu	Pro	Lys…						C0HLL3
Vesp v 5	Asn	Asn	Tyr	Cys	Lys…						P0DMB9

(*) Asn derivative corresponding to N-glycosylation

Fig 3

Complete coding sequence of hyaluronidases isoforms (Vesp v 2A and Vesp v 2B).

Panels A and B show the complete CDS of extracted from the transcriptomic data of Vespa velutina ([7,20]) for Vesp v 2A (341 amino acids, 40012.2 Da) and Vesp v 2B (331 amino acids, 39109.7 Da), respectively. Numbers above the sequences facilitate the localization of the amino acids. In both panels, horizontal lines with arrows located below the sequences indicate the “potential N-glycosylation sites” for each sequence (defined as Asn-Xaa-Ser/Thr sequons, according to the prediction performed at the NetNGlyc 1.0 Server [21]). The only confirmed glycosylated residue (marked with an asterisk below the sequence) is Asn-3 in the Vesp v 2A isoform, as shown in the data presented in Table 1. Besides, in the referred table, the accession numbers assigned to these sequences in the UNIPROT database are shown.

The N-terminal sequence data for both Vesp v 1 and Vesp v 5 show a unique sequence, confirming its purity. Besides their direct analysis by nLC-MS/MS also confirm that most of the peptides found in these analyses correspond exactly to the sequences extracted from the Vespa velutina transcriptomic data ([7]), as shown in Fig 4. As it can be observed, 72% and 87% coverage, for Vesp v 1 and Vesp v 5 respectively, have been experimentally determined by this combination of techniques. An interesting feature for Vesp v 1, is that it is a glycosylated phospholipase; this can be deducted from the fact that nLC-MS/MS studies have not provided any data on the peptide in which Asn-61 is potentially predicted as N-glycosylated (Fig 4A); on the contrary, Asn-40 is not glycosylated, since the peptide containing this amino acid is clearly identified by nLC-MS/MS (Fig 4A). This is therefore another peculiar A1-phospholipase, since they are not usually glycosylated (so far, this had been only described for two phospholipases: Dol m I from Dolichovespula maculata ([25]) and for Sol i 1, from the imported fire ants ([26]). Moreover, the glycosylation of Vesp v 1 is also confirmed by the higher apparent molecular weight this protein exhibits in an SDSPAGE (36.1kDa, Fig 1), in comparison with the 34.0kDa that correspond to the polypeptide part of its complete CDS (Fig 4).

Fig 4

Complete coding sequence of Vesp v 1 and Vesp v 5, and characterization of its sequences.

Panel A shows the Vesp v 1 CDS extracted from the trancriptomic data of Vespa velutina (304 amino acids, 33957.2 Da), highlighting in yellow the peptides identified by nLC-MS/MS analysis, and in green the N-terminal sequence determined (see Table 1). Moreover the two potential N-glycosylation sites for Asn ([21]) are also indicated by horizontal arrows, but only the second predicted site seems to be glycosylated (Asn-61, as explained in the text). Panel B shows the CDS for Vesp v 5 (202 amino acids, 22717.7 Da), similarly coloured as in panel B for Vesp v 1; no N-glycosylation is predicted for this antigen 5. These complete sequence data are available at UNIPROT database, with the accession numbers indicated in Table 1. Besides, the data from the MS/MS analyses for each protein are available with the PXD015381 as ProteomeExchange identifier at the MS Interactive Virtual Enviroment (MassIVE).

These complete CDS, corresponding to relevant proteins present in the venom of Vespa velutina, have been assigned the corresponding UNIPROT accession numbers, as shown in Table 1, and are now available for further comparison with other homologous venom components described to date. Vesp v 5 exhibits an apparent molecular weight of 23.5kDa in SDSPAGE (Fig 2), close to the 22.7 kDa calculated size from the complete CDS shown in Fig 4 (as expected, antigen 5 is not a glycosylated component).

The major allergen Vesp v 5, and the potential major allergen Vesp v 1, have been purified to homogeneity, and most of their CDS determined (with an 87% and 74% of total coverage, respectively; Fig 4), matching perfectly with the extracted data from the Vespa velutina transcriptome [7]. This also confirms that these sequence data, obtained from the RNA extracted from the venom glands of the hornet species present in China [7], match exactly with the experimental data determined from the isolated natural components from the venom from species present in Europe, where the source material was collected. These data are very relevant, since they show that there have not been evolutive variations in the amino acid sequences of these venom components, in spite of the potential regional variations of the Asian hornet in its original location and the analogous components produced in the venom of Vespa velutina species that entered in Europe in the first decade of the year 2000, and have then expanded its presence throughout several European countries. In addition, it is important to mention that the actual sequences that are presented in this manuscript are the only existing isoforms found in the whole Vespa velutina transcriptome, i.e. no additional isoforms were found for Vesp v 1, Vesp v 5 or the two Vesp v 2 isoforms.

In the case of the two only hyaluronidases isoforms found (named Vesp v 2A and Vesp v 2B), the complete CDS have not been extensively characterized experimentally, but the exact match of the first 10 amino acid residues of each isoform (Fig 3 / Table 1) permits to reasonably think that the whole CDS will be those extracted from the complete transcriptomic database. Nevertheless, the partial characterization of these hyaluronidases isoforms, is completed, apart from the purity shown in the chromatographic peak containing the aforementioned isoforms (Fig 2), also considering that the enzymatic activity for hyaluronidase was specifically measured in fractions “c”, “d” and “e” shown in Fig 2, and as it was the case for the Vespula vulgaris hyaluronidase (Ves v 2) purified by Monsalve et al. [10]. Moreover, our data on the Vesp v 2B isoform, as the most abundant hyaluronidase, is coincident with the data presented by Kolarich et al. [23] for the isoforms of Vespula vulgaris.

These complete CDS allow an overall sequence comparison with the previously known homologous allergen components of diverse Hymenoptera species, being of interest the similarity with other Vespa, Vespula or Polistes species. A remarkable similarity has been found between the components of Vespa and Vespula, much higher than with regard to Polistes. It is particularly striking, as shown in Fig 5, the fact that one of the hyaluronidase isoforms of Vespa and Vespula exhibit 93% sequence identity (and only 73% in the case of the isoform present in Polistes), and that the other isoform exists in Vespula and Vespa and it is not present at all in Polistes (these data can be confirmed by having compared with the sequences available to the date in the existing public sequence databases of both nucleotide and protein sequences, searched with the program BLAST (Basic Local Alignment Tool) [22]).

Fig 5

Alignment of several Hymenoptera hyaluronidases with respect to Vesp v 2 isoforms.

Panel A- Alignment of Vesp v 2 isoforms with the sequences from relevant species available in sequence-databases. The multiple sequence alignment is performed by the program ClustalW ([27]). In the overall alignment, the upper sequence corresponds to Vesp v 2A, and below that, a dot represents identity with the upper sequence, and a dot surrounded in a black square indicates absolute identity among all the aligned proteins (on the other hand, when there is no identity, the corresponding amino acid is shown); finally, the gaps opened by the ClustalW alignment program are represented by “-“. On the right margin of the sequences, the corresponding numbering of each sequence is shown. The sequences compared with the two new Vespa velutina isoforms, shown as Vesp_v_2A and Vesp_v_2B, and shown in the alignment are: two isoforms from Vespula germanica, Ves g 2A (Uniprot Q05FZ1) and Ves_g_2B (Uniprot Q05FZ2), and the hyaluronidases found for Vespa magnifica (Vesp_mg_2, Uniprot P86875) and Polistes dominula (Pol_d_2; NCBI Reference XP_015179722). In all cases, mature proteins are compared (i.e. starting from the N-terminal of the corresponding protein).Panel B summarizes the identity percentages among these homologous hyaluronidases aligned, differentiating the very high similarities of Vesp v 2B with Vespa and Vespula’s hyaluronidase (above), and the somehow lower similarities versus (vs) the Vesp v 2A isoform.

The similarities between the different genera, comparing their phospholipases and antigen 5s are shown in Fig 6 and Table 2, and show the highest similarity of the Asian hornet components with those of the Vespa and Vespula species, in comparison with those of the Polistes species.

Fig 6

Multiple sequence alignment of Vesp v 1 and Vesp v 5 with other homologous Hymenoptera components.

Panel (A) and (B) show the alignment of the complete CDS for phospholipases and antigen 5s respectively. The complete mature Vesp v 1 and Vesp v 5 sequences are shown, and are compared with the corresponding mature sequences of a homologous representative from Vespa crabro, Vespula vulgaris and Polistes dominula. The colouring scheme for the alignments is the same than in Fig 5A. On the right margin of the sequences, the corresponding numbering of each sequence is shown. In panel (A) the accession codes of the proteins compared with Vesp v 1 are: Vesp_c_1 (Uniprot P0CH87), Ves_v_1 (Uniprot P49369) and Pol_d_1 (Uniprot Q6Q252). The accession codes of the proteins compared with Vesp v 5 (panel B) are: Vesp_c_5 (Uniprot P35782), Ves_v_5 (EMBL CAB42887.1) and Pol_d_5 (Uniprot P81656).

Table 2

Sequence identity and similarity of Vesp v 1 and Vesp v 5 in comparison with the homologous components of other Hymenoptera.

Data are obtained after the sequence alignments shown in Fig 6, the values shown correspond to the percent identity, and the percent similarity is shown in brackets (similarity refers to residues having total identity between the sequences, plus those amino acids that are considered to be conservative substitutions as explained in [27]).

Identiy % (similarity %) with respect to Vespa velutina components
	Phospholipases	Antigen 5s
Vespa crabro	69 (78)	88 (93)
Vespula vulgaris	61 (76)	66 (77)
Polistes dominula	53 (71)	58 (75)

The availability of the purified components from V.velutina venom will allow to confirm their individual relevance as allergens in patients sensitized to V.velutina venom. Vesp v 5 had already been described as the major allergen of V.velutina venom [6], but the phospholipase Vesp v 1 cannot be discarded also as a major allergen in Hymenoptera-sensitized patients, as previously shown in several studies in which these two allergenic components have been shown to differently affect different allergic patients [10] and also considering the described intrinsic importance as allergens of phospholipases [28]. These pure components (Vesp v 1 and Vesp v 5) have been specifically prepared as “detection reagents” for measuring sIgE, following the procedure described by Erwin et al. [29] and will be tested in patients that have shown anaphylactic shocks after being stung by V.velutina.

The clinical data that will be obtained in future experiments with the use of these isolated components, as well as the overall data of the clinical history of patients being already treated with different commercially available preparations, will confirm if the clear similarity existing among Vespa and Vespula components justifies that the treatment of these patients with Vespula-containing preparations is really being effective in protecting these patients, as already shown for Vespa spp.-sensitized patients [30,31], that had been protected by immunotherapy with Vespula commercial preparations, in contrast with the opinion of other authors who consider that a specific treatment would be more adequate [32], even if they mainly refer to safety issues.

More biochemical and immunological studies, including component-resolved-diagnosis (CRD) with the proteins purified in this work and other components available, are therefore needed to confirm which will be the best treatment for these sensitized patients, also considering that the patients being treated nowadays are very probably patients that have become allergic after stings of the wasps and hornets present in these areas until now (Vespula, Polistes and/or Vespa crabro), but there might be a completely new population of patients who will develop allergenicity by Vespa velutina stings as the culprit insect.

Conclusions

Four important components from the venom of Vespa velutina (Asian hornet) have been purified and partially characterized. Apart from Vesp v 5, the antigen 5 already described as a major allergen, also the A1-phospholipase and two hyaluronidases isoforms have been purified (they are potentially allergenic components, named Vesp v 1, and Vesp v 2A and Vesp v 2B, respectively).

The complete coding sequences (CDS) of these components are now available, after this characterization and having been extracted their CDS from the transcriptome data available for the venom glands of V.velutina.

The purified components will be used to further characterize the sensitization of patients that show anaphylactic shocks after being stung by these Asian hornets, which have invaded several European countries, and treat these patients in the best way possible.

Raw images of SDSPAGEs presented in Figs 1 and 2.

(PDF)

Click here for additional data file.

10 Sep 2019

PONE-D-19-22139

Purification and molecular characterization of phospholipase, antigen 5 and hyaluronidases from the venom of the Asian hornet (Vespa velutina)

PLOS ONE

Dear DR. MONSALVE,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Oct 25 2019 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Paulo Lee Ho, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

3. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

4. Thank you for stating the following in the Financial Disclosure section:

"The author(s) received no specific funding for this work, apart from their regular salary."

We note that one or more of the authors are employed by a commercial company: ALK-Abelló

a. Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Please also include the following statement within your amended Funding Statement.

“The funder provided support in the form of salaries for authors [insert relevant initials], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.”

If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.

b. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to  PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests) . If this adherence statement is not accurate and  there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

c. Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: N/A

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The manuscript is technically sound and needs only minor revisions, which are pointed in pdf file together with a few comments and/or observations.

It is written in understandable English. Highlights should be pointed out by the authors in the Abstract emphasizing the contribution of this study.

All the experiments were carried out with scientific and ethical criteria. The results presented in tables and figures, are essentially important so that the reader can follow all the experimental approaches used, as well as the conclusions that they allowed to arrive. All of them are of quality, demonstrate the results obtained and supported the conclusion established by the authors. Images of electrophoretic gels and blots are free from apparent manipulation.

The results obtained here, open new perspectives to further biochemical and immunological studies with the proteins purified in this work and other components available to confirm which will be the best treatment for sensitized patients, that have become allergic after stings of the wasps and hornets, until a new population of patients who will develop allergenicity by Vespa velutina stings, as the culprit insect.

Reviewer #2: This manuscript just describes the molecular characterization and purification of a phospholipase (Vesp v 1), an antigen 5 (Vesp v 5) and two hyaluronidase isoforms (Vesp v 2A and Vesp v 2B) from the Vespa velutina nigrithorax wasp venom (Hymenoptera, Vespidae).

This wasp is known as yellow-legged Asian Hornet. It Is a species of hornet indigenous to Southeastern Asia. It is of concern as an invasive species in some other countries and in Portugal, it predates honey-bees and other insects.

It has been studied for causing major human accidents in the North-Western parts of the Spanish coast.

In case this paper is approved for publication by PlosOne, I would rather suggest the authors to answer the following questions:

- What is effectively the extent of this wasp on human accidents?

- What is the significance of the translational medicine standpoint for this type of research, I´d say, to mitigate allergic reactions (treatment) and better diagnosis?

- How can differences in sensitization to immune reaction between Vespula and Polistes be explained since they are very close phylogenetically (daughter group), since both belong to the Vespidae family?

- The most important concern of this manuscript is: authors used a pool of wasp venoms from all over Europe. Doesn´t this make it difficult because of individual variations in wasp venoms from different regions of Europe? I mean, antigen detection by antibodies should be specific as well as treatment. We must know exactly which immunogenic compounds are present in a venom gland of a specific species for the detection and later medication. Therefore, if you use a pool, how effective can these two (diagnosis and treatment) factors be, in addition to those molecules evidenced in this study? Is there any study showing that there are differences between venoms of this wasp, due to food, from different regions?

- Is there any specificity and / or similarity between the isolated molecules and those already well-known from other sources of hymenoptera and / or other animals?

- Actually, the discussion of the manuscript is contained from page 335 to 362. Therefore, it is quite powerless and does not, in my view, match the level of the journal.

- Finally, there is no consistent discussion of isolated molecules and effective actions to solve medical and immunological problems.

- Which chromatography method was used: FPLC or HPLC?

- What is a "direct analysis from the protein in solution"?

- No reagents used in the study have the company's city and country of origin.

- The figures are not of good quality and need to be improved.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

Submitted filename: PONE-D-19-22139_reviewer.pdf

Click here for additional data file.

11 Oct 2019

RESPONSES HAVE BEEN INCLUDED IN THE DOCUMENT "RESPONSE TO REVIEWERS"

Submitted filename: Response to Reviewers.docx

Click here for additional data file.

11 Nov 2019

Purification and molecular characterization of phospholipase, antigen 5 and hyaluronidases from the venom of the Asian hornet (Vespa velutina)

PONE-D-19-22139R1

Dear Dr. MONSALVE,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

With kind regards,

Paulo Lee Ho, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: (No Response)

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: (No Response)

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: No

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: I believe all the corrections made by the authors are quite satisfactory and the present study, now deserves to be published in PlosOne.

Reviewer #3: This manuscript by Rafael et al. aims to purify and identify the potential allergenic components from Vespa velutina venom. The phospholipase, antigen 5 and two hyaluronidase isoforms have been well confirmed and partially characterized in this work. The revised manuscript has profoundly addressed the comments contributed by reviewers. I have no additional comments, and this manuscript is now suitable for publication.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Reviewer #3: No

27 Dec 2019

PONE-D-19-22139R1

Purification and molecular characterization of phospholipase, antigen 5 and hyaluronidases from the venom of the Asian hornet (Vespa velutina)

Dear Dr. MONSALVE:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

For any other questions or concerns, please email plosone@plos.org.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Paulo Lee Ho

Academic Editor

PLOS ONE